Seizures occur more frequently in the neonatal period than in the remainder of childhood. Neonatal seizures can have different aetiologies. Inborn errors of metabolism are rare causes of seizures in the newborn. However, they are an important cause of intractable neonatal seizures, accounting for 30% of cases. Diagnosis is necessary for timely institution of appropriate treatment and is important in determining clinical outcome. As these are genetic conditions, it allows for appropriate genetic counselling. We describe the clinical presentation of neonatal seizures and the investigation findings in symptomatic neonatal seizures and epilepsy syndromes that arise in the neonatal period. The approach in diagnosis and investigation of an underlying inborn error of metabolism is described and inborn errors of metabolism that are important causes of neonatal seizures are reviewed.
Neonatal seizures have a vast number of possible aetiologies.
Common aetiologies include neonatal encephalopathy (60%), intracranial infection (5-10%), intracranial haemorrhage, developmental malformations and correctable metabolic disturbances such as hypoglycaemia and derangement of electrolytes (example, sodium, calcium and magnesium) 10 . To some degree the type of seizure may suggest the aetiology. Focal clonic or tonic seizures can be associated with focal injury such as cerebral infarcts or haemorrhages, hypoglycaemia, hypocalcaemia, hypomagnesaemia and infections of the central nervous system (CNS). Generalised tonic seizures, motor automatisms and some myoclonic seizures are associated with more diffuse brain injury such as hypoxia-ischaemia, bilateral infarcts or extensive CNS infections 8 . However these seizures are not exclusive to the mentioned aetiologies and a comprehensive search for treatable causes is still required. Once these common aetiologies have been excluded or seem unlikely, it is important to consider rarer causes.
Neonatal Seizures: When to Consider and How to Investigate for an Inborn Error of Metabolism INtroduCtIoN
Seizures can occur in approximately 0.5% of term neonates and up to 22.2% of preterm neonates 1-5 , which varies based on the range of post-conceptual ages and the interobserver variation 6 . Neonatal seizures are unique and traditionally differ from seizures occurring at other times of life in terminology and semiology. Certain aetiologies are unique to the neonatal period. Seizures were initially classified based on clinical observation alone 7 , then extended to include electroencephalographic (EEG) information 8 . A further multi-axial classification comprising 4 dimensions of diagnostic accuracy, brain-region specificity, maturation and aetiology was then proposed 6 . Most recently, neonatal seizures have been subsumed into the wider seizure classification applied to seizures in children and adults under development by the International League against Epilepsy 9 . The term "neonatal seizures" in this article, therefore refers primarily to the chronological timeframe within which the seizures occur.
CorrECtAblE trANSIENt MEtAbolIC dISturbANCES tHAt CAuSE SEIzurES Hypoglycaemia
Hypoglycaemia is a correctable cause of neonatal seizures. It can occur for many reasons and can be a presenting feature in several metabolic diseases. It is important to exclude common causes like intrauterine growth retardation, hyperinsulinism secondary to maternal diabetes and sepsis. Hypoglycaemia secondary to systemic diseases like sepsis is easily correctable with glucose infusion rate slightly greater than or equal to basal glucose oxidation rate (5-7mg/kg/min in neonates). Higher glucose infusion requirements may point to a possible underlying inborn error of metabolism (IEM).
Normoglycaemia during fasting is maintained by gluconeogenesis (to produce glucose) and fatty acid oxidation (to provide alternative energy substrates). Hence, hypoglycaemia associated with IEM can be due to primary or secondary defects in glucose production, such as glycogen storage disease or galactosaemia; or as a result of defects in fatty acid oxidation. Testing of urine for ketone bodies will help to differentiate between the 2 causes.
Neonates with fatty acid oxidation defects have an impaired capacity to use stored fat as a source of energy during periods of fasting. Other clinical features include hepatomegaly, myopathy and Reye syndrome. Urine organic acid analysis, measurement of plasma carnitine and acylcarnitine profile are the main line of investigations. Confirmatory studies can be performed on skin fibroblast or mutation analysis.
Timing of the investigations performed in hypoglycaemia is key as insulin, growth hormone and cortisol measurements can only be sensibly interpreted if taken when hypoglycaemic. Blood samples for the following investigations should be quickly taken:
 Endocrine: Insulin, C-peptide, cortisol, growth hormone  IEM: amino acids, lactate, acylcarnitines, free fatty acids and ketone bodies.
Hypocalcaemia
Hypocalcaemia remains an important cause of neonatal seizures and is an easily correctable cause. In a large series of 137 neonates with seizures 7 , hypocalcaemia was diagnosed in 20% of cases. Seizures can occur early after birth, but most occurred in day 4-7 of life. Neonates with hypocalcaemia secondary to prematurity, birth asphyxia and maternal diabetes tend to present in the first 72 hours. Later presentation usually occurs in those secondary to high phosphorus dietary intake, primary or secondary dysregulation of the parathyroid-renal axis, hypomagnesaemia and renal insufficiency 11 . The types of seizures are variable, but focal convulsions, including hemi convulsions, are common. In cases due to simple hypocalcaemia, the prognosis is excellent.
Hypomagnesaemia
Transient hypomagnesaemia often occurs in association with hypocalcaemia and this is easily correctable with correction of the calcium levels 11 . However, in some cases, the primary problem is hypomagnesaemia and the Mg levels are often lower. Some of these conditions are genetic in nature and can be familial 12 .
Hypomagnesaemia with secondary hypocalcaemia (HSH) is an autosomal recessive disorder caused by mutations in the gene encoding TRPM6 located on chromosome 9q22 13 . This is a member of the transient receptor potential channel family and mutations lead to defective intestinal magnesium absorption and renal tubular loss. Many genetic forms of primary renal hypomagnesaemia have also been described, including those occurring with hypercalciuria 14 , normocalciuria and hypocalciuria.
The preceding section has described symptomatic neonatal seizures. These are usually short-lived and self-limited or respond well to treatment of the seizures or the underlying aetiology. Persistent seizures despite adequate treatment may prompt evaluation for the epilepsy syndromes that arise in the neonatal period and further investigation for an underlying aetiology, including IEMs. Inborn errors of metabolism are rare causes of seizures in the newborn accounting for <1% of all neonatal seizures. However when one considers the sub-group of persistent intractable seizures then the incidence rises to around 30%. IEM are extremely important to detect for 2 reasons: they may be treatable and the genetic basis means there is a significant risk (usually 25%) of recurrence in future pregnancies. Some points should be highlighted regarding the history that may be relevant to an IEM. These Proceedings of Singapore Healthcare  Volume 19  Number 2  2010 include noting any previous unexplained neonatal illness or death, taking an extensive three pedigree family history and enquiring about consanguinity.
ClINICAl ANd EEG pAttErNS of NEoNAtAl EpIlEpSy SyNdroMES
In the presence of seizures which are treatmentrefractory and/or persist beyond the neonatal period, consideration of neonatal epilepsy syndromes is required. Epilepsy syndromes in the neonatal period comprise 2 entities with benign outcome and 2 entities with poor prognosis. Migrating partial seizures of infancy will not be discussed in the context of this article as links to inborn errors of metabolism have not been described.
Benign familial neonatal seizures (BFNS) have onset on day 2 or 3 of life in 80% and presents with asymmetric tonic or oculo-facial seizures. Myoclonic or generalised seizures or epileptic spasms are not seen in this syndrome and neurological examination is normal. EEG shows the pattern of "theta pointu alternant" (bursts of rhythmic theta activity (4-7Hz) that may be mixed with sharp waves and alternate between hemispheres) and during seizures the ictal rhythm is focal. There is a positive family history and mutation analysis shows that these patients have potassium channelopathies of KCNQ2 and KCNQ3 15 . Many do not require treatment or respond readily to anticonvulsant therapy.
Benign idiopathic neonatal seizures (BINS) have onset on day 5. In contrast to BFNS clonic and apnoeic seizures occur, as can status epilepticus. Neurological examination is typically normal or moderately abnormal. EEG again can show "theta pointu alternant". Unlike BFNS there is no family history. Interestingly, this entity has become rare since it was initially described 15 . BINS is characterised by seizures which are easily controlled by first-line anticonvulsant therapy. Transient dysmaturity may be seen which resolves on long term follow-up, though few cases have been reported since the syndrome was first described in the 1970s.
The 2 major epileptic encephalopathies of early infancy are distinguished from the preceding benign epilepsy syndromes by the presence of sustained suppression-burst on EEG. The suppression burst pattern is defined as bursts of high voltage (150-350µV) slow waves with intermixed spikes lasting 3-5 seconds and interspersed with attenuation lasting 5-10 seconds ( Fig. 1 ). It is a non-specific response of the brain to a variety of insults and indicative of a severe degree of cerebral dysfunction and may represent interruption in the cortical/sub-cortical neuronal circuitry. With the exception of toxic aetiologies due to high dose medications such as phenobarbital, the presence of this pattern imparts a guarded prognosis. In the majority of neonatal cases with a clear aetiology, serial EEGs show resolution of suppression-burst or progression to electro-clinical silence within a fortnight. If the suppression burst pattern is sustained beyond 2 weeks the epileptic encephalopathies in early infancy become increasingly likely. There are 2 syndromes defined in the literature: early infantile epileptic encephalopathy (Ohtahara Syndrome) and early myoclonic encephalopathy (EME).
Ohtahara's syndrome and early myoclonic encephalopathy are the earliest of the agedependent epileptic encephalopathies. Agedependent epileptic encephalopathies are epilepsy syndromes where aggressive EEG paroxysmal activity coupled with multiple intractable seizures and progressive psychomotor regression 16 . At each age range, these can manifest in characteristic yet distinct patterns: Ohtahara syndrome and early myoclonic encephalopathy in the neonatal period, West syndrome in infancy and Lennox-Gastaut syndrome in early childhood (continuous spike-wave in sleep and Landau Kleffner syndrome comprise the late onset epileptic encephalopathies). It is not uncommon for children presenting with one epileptic encephalopathy to transition to the next epileptic encephalopathy as they become older. In Ohtahara's original series, 75% of babies with Ohtahara syndrome developed West syndrome and 60% of these went on to develop Lennox-Gastaut syndrome 17 .
Ohtahara syndrome may begin in-utero 18 and 75% present in the first month of life, with all cases presenting by 3 months of life. Seizures are typically tonic seizures and focal motor seizures such as hemi-convulsions, with myoclonic seizures being rare 17, 18 . The interictal EEG is described as the typical suppression-burst pattern with suppression phases of 2 to 5 seconds and can be asymmetrical in up to two-thirds and does not vary with circadian cycle. During seizures the ictal EEG shows flattening of the EEG with associated slowing, rhythmic fast or slow activity. Classically the aetiology is predominantly organic brain lesions 19 -22 , though a significant proportion are of unknown aetiology. Inborn errors of metabolism have been associated with Ohtahara syndrome 23 . Mortality is high in the early years irrespective of cause with seizures remitting by school age but severe developmental impairment being the rule 24 .
Early myoclonic encephalopathy was first described in 1978 25 . Onset of seizures will occur by the first week of life in 76% and by the first month of life in 96%. As with Ohtahara syndrome, the onset may be prenatal. Seizures are partial/ fragmentary myoclonus and partial motor seizures with massive myoclonus. Tonic spasms appear late. Clinical examination demonstrates hypo-or hypertonia. Interictal EEG is characterised by suppression-burst with short 1-5 second bursts and marked interburst flattening. Inborn errors of metabolism are frequently implicated in the aetiology 26 and investigations should proceed appropriately (see Table 1 , preceding page). However, as with Ohtahara syndrome, the aetiology is unknown in a significant proportion 27 .
Though the aetiologies between Ohtahara syndrome and early myoclonic encephalopathy may seem distinct based on classical descriptions of the syndromes, there are both structural and metabolic aetiologies described within each entity. Additionally some inborn errors cause structural lesions. Peroxisomal disorders can produce migration defects. Pyruvate dehydrogenase deficiency, nonketotic hyperglycinemia, and maternal phenylketonuria preferentially cause a dysgenetic corpus callosum. Abnormal metabolism of folic acid causes neural tube defects, whereas defects in cholesterol metabolism may produce holoprosencephaly 28 . It has therefore been proposed that the 2 syndromes represent the same pathological process manifesting at different points 29 .
It may be difficult to determine the exact nature of the seizures and epilepsy syndrome at presentation. Some features of the seizure type and presentation may hint at the aetiology. However these are not specific to a condition and ultimately a comprehensive inclusive approach to differential diagnosis and investigation is necessary in patients with medically refractory seizures despite adequate treatment.
IEM tHAt typICAlly prESENt AS NEoNAtAl ENCEpHAlopAtHy
This group of disorders presents with neonatal encephalopathy, which may be defined as a triad of altered consciousness, reduced tone and seizures. These conditions are often associated with other biochemical derangements such as hypoglycaemia, metabolic acidosis and hyperammonaemia 29 . The main disorders to consider here are disorders of intermediary metabolism such as organic acidurias and urea cycle defects. The diagnosis can usually be established in this situation with a combination of urine organic and amino acids, plasma lactate and plasma amino acids. There are specific emergency treatments for this group such as dialysis, intravenous dextrose, dietary protein restriction, carnitine and vitamin medications which improve the condition. Once the underlying disorder is treated, the seizures usually stop. EEG patterns are relatively non-specific except for the comb-like rhythm (monophasic runs of 5-7 Hz mu-like activity in the central regions during waking and sleep) seen in maple syrup urine disease 30 .
IEM tHAt typICAlly prESENt IN tHE NEWborN pErIod WItH SEIzurES AS tHE prEdoMINANt SyMptoM
In this group of IEM the initial biochemical tests are usually unremarkable and specific metabolic tests must be requested in order to make the diagnosis. sulphite oxidase and molybdenum cofactor deficiency lead to an increase in urinary sulphite, elevation of urinary thiosulphates and elevation of plasma and urinary S-sulfocysteine levels 32 .
Patients may also have a low plasma homocysteine, cystine concentration and high plasma taurine concentration. In addition, patients with molybdenum cofactor deficiency have low plasma urate. There is no treatment for the neonatal onset form of these disorders. They are usually fatal conditions in early infancy 33 .
Non-ketotic Hyperglycinaemia
Non-ketotic Hyperglycinaemia (NKH) is a devastating metabolic condition caused by a defect in the glycine cleavage system leading to an accumulation of glycine in the central nervous system. The classical form of NKH presents with intractable seizures early in the neonatal period with descent into coma often requiring ventilatory support. There is usually no accompanying biochemical abnormalities on routine laboratory tests and the diagnosis requires lumbar puncture to demonstrate a raised cerebospinal fluid (CSF): plasma glycine ratio of >0.04 34 . Confirmation of the diagnosis is by liver glycine complex enzyme assays 35 or mutation analysis. Therapies including sodium benzoate and dextromethorphan have not been useful in these cases and there is a high mortality and morbidity rate 36, 37 . Seizures are intractable in these patients and sodium valproate should be avoided as it inhibits glycine metabolism 38 . Vigabatrin has been reported to cause deterioration 39 .
pyridoxine dependent and pyridoxine responsive Seizures 40
Seizures in the newborn period responding to pyridoxine therapy are a well recognised entity. However over the last few years the biochemical and genetic basis of this condition has become clearer. The condition arises due to mutations in the ALDH7A1 gene which encodes the protein antiquitin 41 . This product is an aldehyde dehydrogenase that is part of the cerebral lysine degradation pathway. The biochemical marker is elevated alpha-aminoadipic semialdehyde (AASA) in the plasma, urine and CSF. This marker remains detectable for many years even after pyridoxine is administered 42 . In some patients it has normalised after effective long-term treatment. Elevated pipecolic acid is an indirect marker of the condition.
Classical pyridoxine dependent seizures present within hours or days of birth with refractory seizures or status epilepticus. Mothers may report unusual foetal movements suggesting in utero seizures. Typically the seizures recur serially or evolve in to status epilepticus despite treatment with standard anticonvulsants but show a response to intravenous or oral pyridoxine. Atypical cases may present with seizures beginning after the neonatal period or with initial response to anticonvulsants followed by medically intractable seizures. The EEG pattern shows abnormal background with slowing and focal, multifocal or diffuse epileptiform discharges. Neuroimaging may be normal but a variety of neuroimaging abnormalities including thinning of the corpus callosum, mega cisterna magna and intracranial haemorrhages have been reported 43 . Administration of intravenous pyridoxine in a patient with pyridoxine-dependent seizures may result in resolution of clinical seizures within minutes and of EEG abnormalities within hours 44 . However a negative response to this does not exclude the diagnosis and patients with suspected pyridoxinedependent seizures should be commenced on oral therapy for a minimum of 2 weeks and monitored for clinical effect. The therapeutic dose range of pyridoxine is broad and varies widely between centres. In some centres, if no response is seen to 100mg pyridoxine then increments of 100mg are added until 500mg has been administered 42 . Prior to the availability of biochemical tests to confirm the diagnosis, it was necessary to re-challenge the patient by withdrawing pyridoxine. This step was often not taken as clinicians and parents were unwilling to allow recurrence of seizures. Wider availability in the near future of biochemical testing and mutation studies will help avoid this practice. Once the diagnosis is established treatment with pyridoxine is life-long. Daily doses of 50 to 500 mg in 1 or 2 divided doses have been used. Although seizure control can be achieved there can be neurodevelopmental delay, which may be related to the timing and dose of pyridoxine. Expressive language defects are the most common problem but motor delay and significant intellectual handicap are also reported 40 .
folinic Acid-responsive Seizures This condition was described following reports of a group of infants with intractable seizures who responded to the administration of folinic acid 45 . These children presented in the first week of life with anticonvulsant-resistant seizures. Investigations of CSF neurotransmitters by high performance liquid chromatography showed an unidentified peak. However more recently these patients have been shown to have mutations in the antiquitin gene responsible for pyridoxine responsive seizures 46 . The relevance of the unidentified compound remains unexplained as does the role of folinic acid in their response. Whether folinic acid is necessary if adequate pyridoxine is administered remains unclear. However until this disorder or variant is further characterised, folinic acid challenge should be carried out in infants who do not respond to pyridoxine.
pyridoxal phosphate responsive Seizures (pyridoxamine phosphate oxidase deficiency)
In this disorder neonates do not respond to pyridoxine but to pyridoxal phosphate. It arises due to deficiency of pyridoxamine phosphate oxidase 47 . Biochemically there are abnormalities in neurotransmitter analysis (increased 3-methoxytyrosine; decreased 5-hydroxyindole acetic acid and homovanillic acid) and CSF and plasma amino acids (raised threonine and glycine) which are due to impaired activity of those enzymes which need pyridoxal phosphate as a cofactor. These biochemical clues are not always present. Mutations in the PNPO gene are described. Neonates with this condition are often premature and have lactic acidosis and hypoglycaemia at presentation. The EEG commonly shows a burstsuppression pattern or focal spikes 48 .
Gamma-aminobutyric acid (GAbA) transaminase deficiency
GABA transaminase deficiency appears to be an extremely rare neurotransmitter disorder 49 . Fits may occur from birth. It is detected by measuring CSF neurotransmitters which show elevated GABA levels. There is no treatment.
Adenylosuccinate-lyase deficiency
This is an autosomal recessive disorder of de novo purine synthesis. It seems to be an extremely rare disorder with fewer than 100 cases described worldwide and in fact the first Asian case report only this year 50 . The severe neonatal form is associated with prenatal growth restriction, fetal and neonatal hypokinesis and a rapidly fatal neonatal encephalopathy 51 . Seizures are characteristically present. If the infant survives this period, there is hypotonia, developmental delay with autistic features. Brain magnetic resonance imaging (MRI) shows extensive white matter change.
In order to make this diagnosis the urine or CSF must be examined for the presence of succinylaminoimitazolecarboxamide riboside (SAICAr) and succinyladenosine (S-Ado). The ratio of these 2 metabolites is also helpful diagnostically, correlating with severity. This is not a routine test even in the specialised metabolic laboratory and so proposed investigation should be discussed with a metabolic specialist. It may be that cases remain undiagnosed as these metabolites would not be detected on routine urine amino or organic acid analysis.
disorders of Serine biosynthesis
The amino acid serine plays an essential role in the development and function of the central nervous system. Consequently disorders in the biosynthetic pathway resulting in low plasma and CSF serine can give rise a severe neurological phenotype including seizures.
3-phosphoglycerate dehydrogenase (3-PGDH) was first recognised in 1996 and since then many cases have been reported 52 . The infantile form causes microcephaly and a severe seizure disorder which may start in the newborn. There is no typical seizure type and many patterns have been described including infantile spasms, tonic-clonic, tonic, atonic, gelastic and myoclonic. The EEG pattern is also variable but hypsarrhythmia and clinical West syndrome have been described 53 . The condition is inherited as an autosomal recessive trait. MRI of brain shows hypomyelination and severe lack of white matter. Treatment with serine has a beneficial effect on seizure control, but does not improve development. There are 2 other disorders described in this pathway; one in a pair of siblings, phosphoserine aminotransferase (PSAT deficiency), and the other in a single case phosphoserine phosphatase deficiency (PSPH). Since the numbers are small it is not possible to know the range of these phenotypes.
Mitochondrial disorders
Mitochondrial disorders frequently present with neurological symptoms. They can present in the neonatal period with encephalopathy, hypotonia and intractable seizures. Elevated lactate, both in the plasma and cerebrospinal fluid, can be a prominent feature. Neuroradiological findings may be non-specific or show high signal on T2 or FLAIR sequences, abnormal signal on diffusion-weighted imaging and elevated lactate on MR spectroscopy. Cerebral atrophy and white matter changes are reported in neonates 54 .
Diagnostic tests include spectrophotometric enzyme assays on muscle and functional studies of intact mitochondria in the organs involved. Molecular genetic studies for mutations in the mitochondrial and nuclear DNA are also increasingly utilised. There are no satisfactory treatments for this group of IEMs. Various vitamins and co-factors may be tried but are rarely helpful. Glucose transporter type 1 (Glut-1) deficiency GLUT-1 deficiency syndrome is an inborn error of glucose transport. A defect in the glucose transport across the blood-brain barrier leads to low cerebrospinal fluid glucose levels in the absence of hypoglycaemia. Patients often present with infantile epileptic encephalopathy associated with delayed neurological development, microcephaly and spasticity 58 . The severity of the seizures can range from generalised tonic-clonic seizures to frequent absence seizures. Diagnosis is suggested by low glucose levels in the cerebrospinal fluid and a low CSF: plasma glucose ratio 59 . Confirmation of the diagnosis is by glucose uptake studies in erythrocytes and molecular analysis of the GLUT-1 gene. Patient can be treated by using a ketogenic diet to provide an alternative source of fuel to the brain 60 . The onset of seizures is usually towards the end of the first year of life but rarely neonatal presentation has been reported.
Holocarboxylase Synthetase deficiency

Cerebral Creatine deficiency Syndromes
There are 3 disorders of creatine metabolism that cause seizures. Two are autosomal recessive: guanidinoacetate methyltransferase deficiency (GAMT) and Arginine: glycine amidinotransferase deficiency (ADAT) and the third is an X-linked deficiency of the creatine transporter SLC6A8 61 . They commonly present as mental retardation especially of speech and language and epilepsy. They more often present beyond the neonatal age range in early pre-school period but can result in neonatal seizures 62 . Magnetic resonance spectra (MRS) of brain has been helpful in the diagnosis of this disorder as it can show extremely low levels of cerebral creatine. Biochemical investigations are urine creatine: creatinine, Acid alpha-glucosides (GAA) levels and ultimately genetic confirmation of mutations in the particular gene.
Treatment with creatine improves the seizures associated with GAMT and ADAT but does not overcome the transport disorder and there is no satisfactory treatment currently available for this defect.
Succinic Semialdehyde dehydrogenase deficiency (SSAdH)
This is a disorder of GABA metabolism. More usually onset of seizures occurs in association with mild to moderate developmental delay from late infancy to childhood but neonatal seizures have been reported 63 . Biochemically there is elevation of 4-hydroxybutyric acid which is detectable in urine organic acid analysis.
ApproACH to ASSESSMENt ANd INvEStIGAtIoN
The thorough investigation of seizures may involve extensive metabolic tests. Therefore it is reasonable to approach the problem in a stepwise manner (Fig. 2) . Initial assessment after history and examination includes baseline blood gas, calcium, glucose, magnesium, plasma ammonia and plasma lactate. If correctable abnormalities are detected and treated with resolution of seizures, no further investigation may be required. If seizures persist despite adequate treatment and there are clinical and biochemical features suggestive of an IEM the next stage is urine amino and organic acids, plasma acylcarnitine profile and plasma amino acids. These tests will highlight a disorder of intermediary metabolism in which the seizures are part of a larger encephalopathic picture. If second-line tests are negative and seizures remain refractory to treatment the next stage of investigation includes CSF neurotransmitters, CSF glucose, amino acids and lactate with paired plasma glucose, amino acids and lactate, urine sulphocysteine, plasma uric acid and urine alpha aminoadipic acid. Meanwhile a pyridoxine challenge should be carried out. If these are negative purine analysis can be considered. Evaluation for possible neonatal epilepsy syndromes may, in the absence of a definitive etiology, still permit prognostication and guide treatment of seizures.
CoNCluSIoN
The aetiology of neonatal seizures is wide-ranging. Although inborn errors of metabolism are a rare cause of neonatal seizures, they are extremely important to consider as their detection allows appropriate genetic counselling and may permit specific therapy. If the investigations described above are pursued in a timely fashion then one is unlikely to miss an IEM and appropriate treatment can be accordingly commenced. 
